Statement: Unlike the secondary trial, the primary trial does not record any instances of Anemia, Dyspepsia, Nausea or vomiting.
Primary_evidence: Adverse Events 1:   Total: 2/35 (5.71%)   Gastroesophageal reflux disease * 1/35 (2.86%)   Ductal carcinoma in situ * 1/35 (2.86%)
Secondary_evidence: Adverse Events 1:   Total: 22/41 (53.66%)   Anemia 1/41 (2.44%)   Dyspepsia 1/41 (2.44%)   Mucositis oral 1/41 (2.44%)   Nausea 3/41 (7.32%)   Vomiting 1/41 (2.44%)   Pain 3/41 (7.32%)   Allergic reaction 1/41 (2.44%)   Infections and infestations - Other, specify:  [1]1/41 (2.44%)   Vascular access complication 3/41 (7.32%)   Alanine aminotransferase increased 1/41 (2.44%)